The β3-Adrenoreceptor Agonist Mirabegron for the Treatment of Combined Pre- and Post-Capillary Pulmonary Hypertension: New Pathway or Dead End?
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2780 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Micha T Maeder. Beteiligte Einrichtung: Cardiology Department, Kantonsspital St. Gallen, St. Gallen, Switzerland. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Heart Failure. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
In patients with heart failure (HF), pulmonary hypertension (PH) is common and a marker of an advanced disease stage with poor exercise tolerance and a serious prognosis. Independent of the underlying cardiac disease, PH is the result of the backward transmission of an elevated left atrial (LA) pressure into the pulmonary veins leading to an increase in the mean pulmonary artery wedge pressure (mPAWP) and thereby also the mean pulmonary artery pressure (mPAP). Initially, this is a purely passive phenomenon with a normal transpulmonary gradient and pulmonary vascular resistance (PVR), respectively (isolated post-capillary PH). In more advanced disease stages, pulmonary vascular remodelling with a rise in PVR may occur, and the mPAP is the result of both an elevated mPAWP and an elevated transpulmonary gradient (i.e. the product of PVR and cardiac output), a constellation referred to as combined preand post-capillary PH (CpcPH). Presence of CpcPH is particularly relevant for patients with HF with preserved ejection fraction (HFpEF), because in contrast to HF with reduced ejection fraction (HFrEF) there are still very limited options to treat HFpEF and thereby to lower mPAWP and potentially also PVR.1,2 Several trials evaluating the impact of drugs specifically targeting the pulmonary vasculature (drugs approved for the treatment of pulmonary arterial hypertension) have been conducted in patients with HFpEF and PH with overall mixed results.3–7 On this background, researchers have made efforts to develop innovative treatments for CpcPH. In the present issue of the Journal, Garcia-Alvarez et al.8 report the results of the randomized
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cardiology Department, Kantonsspital St. Gallen, St. Gallen, Switzerland.
- University of Basel, Basel, Switzerland.
Zitieren
APA
Maeder, M. T. (2023). The β3-Adrenoreceptor Agonist Mirabegron for the Treatment of Combined Pre- and Post-Capillary Pulmonary Hypertension: New Pathway or Dead End?. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2780
Vancouver
Maeder MT. The β3-Adrenoreceptor Agonist Mirabegron for the Treatment of Combined Pre- and Post-Capillary Pulmonary Hypertension: New Pathway or Dead End?. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2780
BibTeX
@article{Maeder2023,
author = {Maeder, Micha T},
title = {The β3-Adrenoreceptor Agonist Mirabegron for the Treatment of Combined Pre- and Post-Capillary Pulmonary Hypertension: New Pathway or Dead End?},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2780}
}
EUVIMED